Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo.
Launched by OMAN MEDICAL SPECIALITY BOARD · Oct 18, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare the effectiveness of three different medications—metoclopramide, promethazine, and prochloroperazine—in treating acute peripheral vertigo, which is a type of dizziness often accompanied by nausea or vomiting. The study is taking place in emergency departments across three hospitals in Oman and aims to find out which of these medications works best for patients experiencing these symptoms.
To participate in this trial, individuals must be between the ages of 18 and 60 and have experienced acute peripheral vertigo with a significant level of nausea or vomiting, starting within the last three days. However, people over 60 years old, those with certain medical conditions like epilepsy or dementia, and pregnant women are not eligible. Participants will receive one of the three medications and will be monitored to see how well it helps with their symptoms. This study is currently recruiting participants and will continue until August 2024.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • □ Acute peripheral vertigo with nausea or vomiting (vas, visual analog scale \>5) during their emergency department episode of care for which the attending physician recommending antiemetic, onset with in 3 days .
- • Age( 18- 60).
- Exclusion Criteria:
- • • Age \>60.
- • Any organic brain disease (Clear central cause; "malignancy with brain metastasis".)
- • History of epilepsy
- • Pregnancy.
- • Dementia, Parkinson's disease
- • Abnormal vital signs
- • Any known drug allergy to the study drugs
- • Undergoing chemotherapy or radiotherapy
- • Mechanical bowel obstruction or perforation, gastrointestinal bleeding
- • Inability to understand study explanation or outcome measures (any reason)
- • Patients who refused to participate study.
About Oman Medical Speciality Board
The Oman Medical Specialty Board (OMSB) is a leading regulatory and educational authority dedicated to advancing medical education and healthcare standards in Oman. Established to enhance the quality of medical training and practice, OMSB plays a pivotal role in overseeing clinical trials, ensuring they adhere to rigorous ethical and scientific standards. By fostering collaboration between healthcare professionals, researchers, and institutions, OMSB aims to promote evidence-based medicine and drive innovation in clinical practices, ultimately improving patient outcomes and healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Muscat, , Oman
Patients applied
Trial Officials
Asma Al Buraiki, MD
Principal Investigator
Oman Medical Speciality Board
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials